

Government Gazette

of the State of

New South Wales

Number 14–Health and Education
Friday, 15 January 2021

The New South Wales Government Gazette is the permanent public record of official NSW Government notices. It also contains local council, non-government and other notices.

Each notice in the Government Gazette has a unique reference number that appears in parentheses at the end of the notice and can be used as a reference for that notice (for example, (n2019-14)).

The Gazette is compiled by the Parliamentary Counsel's Office and published on the NSW legislation website (www.legislation.nsw.gov.au) under the authority of the NSW Government. The website contains a permanent archive of past Gazettes.

To submit a notice for gazettal, see the Gazette page.

ISSN 2201-7534

By Authority
Government Printer

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Withdrawal of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation 2008* an Order has been made on **Dr Shervin Manoj PRASAD (MED0001180627)** of LETHBRIDGE PARK NSW 2770, prohibiting him until further notice, as a medical practitioner, from supplying or having possession of drugs of addiction as authorised by clause 101 of the Regulation and issuing a prescription for a drug of addiction as authorised by clause 77 of the Regulation.

This Order is to take effect on and from 24 December 2020.

Dated at Sydney, 22 December 2020.

ELIZABETH KOFF
Secretary, NSW Health

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Withdrawal of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation* 2008 an Order has been made on **Dr Gurmeet Kaur Gilhotra MED0001057796** of Five Dock, NSW 2046, prohibiting her until further notice, as a medical practitioner, from supplying or having possession of drugs of addiction as authorised by clause 101 of the Regulation and issuing a prescription for a drug of addiction as authorised by clause 77 of the Regulation.

This Order is to take effect on and from 24 December 2020.

Dated at Sydney, 23 December 2020.

ELIZABETH KOFF
Secretary, NSW Health

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Withdrawal of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation 2008* an Order has been made on **Dr Khanh Cong Huynh (MED0001180947)**, of TUGGERAWONG NSW 2259, prohibiting him until further notice, as a medical practitioner, from supplying or having possession of drugs of addiction as authorised by clause 101 of the Regulation and issuing a prescription for a drug of addiction as authorised by clause 77 of the Regulation.

This Order is to take effect on and from 24 December 2020.

Dated at Sydney, 23 December 2020.

ELIZABETH KOFF
Secretary, NSW Health

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Withdrawal of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation 2008* an Order has been made on **Dr Sanjeevan NAGULENDRAN (MED0001669095)**, of CASTLE HILL NSW 2154, prohibiting him until further notice, as a medical practitioner, from supplying or having possession of drugs of addiction as authorised by clause 101 of the Regulation and issuing a prescription for a drug of addiction as authorised by clause 77 of the Regulation.

This Order is to take effect on and from 24 December 2020.

Dated at Sydney, 23 December 2020.

ELIZABETH KOFF
Secretary, NSW Health

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Withdrawal of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation* 2008 an Order has been made on **Dr Pavlo Bilokopytov MED0002076754** of Salamander Bay, NSW 2317, prohibiting him until further notice, as a medical practitioner, from supplying or having possession of drugs of addiction as authorised by clause 101 of the Regulation and issuing a prescription for a drug of addiction as authorised by clause 77 of the Regulation.

This Order is to take effect on and from 24 December 2020.

Dated at Sydney, 23 December 2020.

ELIZABETH KOFF
Secretary, NSW Health

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Authorisation to supply a restricted substance – estradiol transdermal patch

I, Judith Mackson, Chief Pharmacist, a duly appointed delegate of the Secretary, NSW Health, make this authorisation pursuant to clause 42A(1)(a) of the *Poisons and Therapeutic Goods Regulation 2008* (NSW) [the Regulation]. Pursuant to clause 42A(2) of the Regulation, the authorisation is granted subject to conditions.

JUDITH MACKSON
Chief Pharmacist
(Delegation Number PH626)

23 December 2020

Authorisation to supply a preparation of the restricted substance estradiol transdermal patch (Substitute Medicine) instead of the preparation prescribed that is a medicine in short supply (Short Supply Medicine)

1 Authorisation

This order authorises a pharmacist to supply the corresponding listed preparation of estradiol transdermal patch (Substitute Medicine) on the prescription of an authorised practitioner where the preparation of the estradiol transdermal patch prescribed is in short supply (Short Supply Medicine), as notified by the Therapeutic Goods Administration's Serious Shortage Substitution Notice, Reference Number SSSN 21-02:

Short Supply Medicine	Substitute Medicine
ESTRADOT 75 estradiol 75 microgram transdermal drug delivery system sachet (ARTG 97565)	**CLIMARA 75** estradiol 75 microgram/day transdermal drug delivery system sachet (ARTG 73963)

2 Conditions

a. The Short Supply Medicine remains on a current notice that is published by the Therapeutic Goods Administration as a medicine that is in short supply and that may be substituted for the other preparation of the Short Supply Medicine.

b. The patient must present with a valid prescription for the medicine to be substituted for.

c. It is not practicable for the patient to obtain a prescription for the Substitute Medicine from a prescriber before the patient needs the supply of the prescribed medicine.

d. The patient or his/her agent or carer must consent to receiving the Substitute Medicine supplied pursuant to the notice.

e. The pharmacist must be satisfied that in his/her professional judgement, after taking all reasonable steps to obtain all relevant information including discussing the matter with the prescriber if possible, that the patient is suitable to receive the Substitute Medicine, considering factors such as known previous hypersensitivity or severe adverse reaction to excipients.

f. The pharmacist must make a reasonable attempt to inform the prescriber of the change to the prescribed medicine, if possible before supplying the Substitute Medicine.

g. The total quantity of the Substitute Medicine supplied must be equivalent to the number of days supplied on the original prescription. The dose interval varies between brands and if dispensing Climara 75 as the Substitute Medicine, half the number of patches specified in the original prescription for Estradot 75 must be supplied.

h. An estradiol transdermal patch must not be cut or torn.

i. The pharmacist must label the Substitute Medicine with relevant directions for use and the dosage interval, as specified for the relevant Short Supply Medicine in the dosage substitution table below:

Short Supply Medicine	**Substitute Medicine**
ESTRADOT 75 One patch applied twice a week	**CLIMARA 75** One patch applied **once** a week

j. The pharmacist must record full details of the supply in the pharmacy's dispensing record system, including the medicine prescribed and the medicine supplied in its place.

k. The pharmacist must annotate the prescription with details of the medicine supplied.

3 Publication

This Order will be published in the Government Gazette pursuant to clause 42A(1) of the Regulation.

4 Duration

This authority commences on 1 January 2021, and expires on the date that the prescribed medicine ceases to be on a current Serious Shortage Substitution Notice that is published by the Therapeutic Goods Administration as a medicine that is in short supply and that may be substituted for the other preparation of the Short Supply Medicine, or otherwise on a date that this authority is revoked.

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Authorisation to supply a restricted substance – estradiol transdermal patch

I, Judith Mackson, Chief Pharmacist, a duly appointed delegate of the Secretary, NSW Health, make this authorisation pursuant to clause 42A(1)(a) of the *Poisons and Therapeutic Goods Regulation 2008* (NSW) [the Regulation]. Pursuant to clause 42A(2) of the Regulation, the authorisation is granted subject to conditions.

JUDITH MACKSON
Chief Pharmacist
(Delegation Number PH626)

December 2020

Authorisation to supply a preparation of the restricted substance estradiol transdermal patch (Substitute Medicine) instead of the preparation prescribed that is a medicine in short supply (Short Supply Medicine)

1 Authorisation

This order authorises a pharmacist to supply the corresponding listed preparation of estradiol transdermal patch (Substitute Medicine) on the prescription of an authorised practitioner where the preparation of the estradiol transdermal patch prescribed is in short supply (Short Supply Medicine), as notified by the Therapeutic Goods Administration's Serious Shortage Substitution Notice, Reference Number SSSN 21-01:

Short Supply Medicine	Substitute Medicine
ESTRADOT 25 estradiol 25 microgram transdermal drug delivery system sachet (ARTG 97562)	**ESTRADERM MX 25** estradiol 25 microgram / 24 hours (0.75 mg) transdermal drug delivery system sachet (ARTG 67089) OR **CLIMARA 25** estradiol 25 microgram / day transdermal drug delivery system sachet (ARTG 73962)

2 Conditions

a. The Short Supply Medicine remains on a current notice that is published by the Therapeutic Goods Administration as a medicine that is in short supply and that may be substituted for the other preparation of the Short Supply Medicine.

b. The patient must present with a valid prescription for the medicine to be substituted for.

c. It is not practicable for the patient to obtain a prescription for the Substitute Medicine from a prescriber before the patient needs the supply of the prescribed medicine.

d. The patient or his/her agent or carer must consent to receiving the Substitute Medicine supplied pursuant to the notice.

e. The pharmacist must be satisfied that in his/her professional judgement, after taking all reasonable steps to obtain all relevant information including discussing the matter with the prescriber if possible, that the patient is suitable to receive the Substitute Medicine, considering factors such as known previous hypersensitivity or severe adverse reaction to excipients.

f. The pharmacist must make a reasonable attempt to inform the prescriber of the change to the prescribed medicine, if possible before supplying the Substitute Medicine.

g. The total quantity of the Substitute Medicine supplied must be equivalent to the number of days supplied on the original prescription. The dose interval varies between brands and if dispensing Climara 25 as the Substitute Medicine, half the number of patches specified in the original prescription for Estradot 25 must be supplied.

h. An estradiol transdermal patch must not be cut or torn.

i. The pharmacist must label the Substitute Medicine with relevant directions for use and the dosage interval, as specified for the relevant Short Supply Medicine in the dosage substitution table below:

Short Supply Medicine	**Substitute Medicine**
ESTRADOT 25 One patch applied twice a week	**ESTRADERM MX 25** One patch applied twice a week
ESTRADOT 25 One patch applied twice a week	**CLIMARA 25** One patch applied **once** a week

j. The pharmacist must record full details of the supply in the pharmacy's dispensing record system, including the medicine prescribed and the medicine supplied in its place.

k. The pharmacist must annotate the prescription with details of the medicine supplied.

3 Publication

This Order will be published in the Government Gazette pursuant to clause 42A(1) of the Regulation.

4 Duration

This authority commences on 1 January 2021, and expires on the date that the prescribed medicine ceases to be on a current Serious Shortage Substitution Notice that is published by the Therapeutic Goods Administration as a medicine that is in short supply and that may be substituted for the other preparation of the Short Supply Medicine, or otherwise on a date that this authority is revoked.

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Withdrawal of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation 2008* an Order has been made on **Mr Martyn Jon Davies (NMW0001629548)**, of ORANGE NSW 2800, prohibiting him until further notice, as a registered nurse, from having possession of or supplying a drug of addiction as authorised by clause 101 and clause 103 of the Regulation.

This Order is to take effect on and from 13 January 2021.

Dated at Sydney, 8 January 2021.

ELIZABETH KOFF
Secretary, NSW Health

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Withdrawal of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation* 2008 an Order has been made on **Anh Nhi Bui PHA0001795787** of Redfern NSW 2016 prohibiting her, until further notice, as a pharmacist, from supplying or having possession of, or manufacturing any preparation, admixture or extract of a drug of addiction as authorised by Clauses 101(1) and 102 of the Regulation.

This Order is to take effect on and from 18 January 2021.

Dated at Sydney, 13 January 2021

Elizabeth Koff
Secretary, NSW Health